niacinamide has been researched along with Cancer of Colon in 26 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effect of the hypoxia-modulating agents nicotinamide and carbogen on tumor hypoxia, tumor blood perfusion, and proliferative activity in liver metastases of the murine colon carcinoma line C26a." | 7.73 | Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen. ( Bussink, J; Heerschap, A; Kaanders, JH; Lok, J; Punt, CJ; van der Kogel, AJ; van Laarhoven, HW; Verhagen, I, 2005) |
| " We investigated the effect of the hypoxia-modulating agents nicotinamide and carbogen on tumor hypoxia, tumor blood perfusion, and proliferative activity in liver metastases of the murine colon carcinoma line C26a." | 3.73 | Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen. ( Bussink, J; Heerschap, A; Kaanders, JH; Lok, J; Punt, CJ; van der Kogel, AJ; van Laarhoven, HW; Verhagen, I, 2005) |
| " Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%)." | 2.76 | Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. ( Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011) |
| " Pharmacokinetic sampling was performed in all patients; preliminary tumor response was also assessed." | 2.71 | Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. ( Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D, 2005) |
| " In BRAF-mutant melanomas, orally bioavailable B-Raf inhibitors, such as vemurafenib, achieve dramatic responses initially, but this is followed by rapid emergence of resistance driven by numerous mechanisms and requiring second-generation treatment approaches." | 1.43 | B-Raf Inhibition in the Clinic: Present and Future. ( Fiskus, W; Mitsiades, N, 2016) |
| "Crizotinib (PF02341066) is a dual MET and ALK inhibitor and approved for the treatment of a subset of non-small cell lung carcinoma and in clinical development for other malignancies." | 1.39 | Crizotinib induces PUMA-dependent apoptosis in colon cancer cells. ( He, K; Yu, J; Zhang, L; Zheng, X, 2013) |
| "Sorafenib + vorinostat treatment activated the c-Jun NH(2)-terminal kinase pathway, which was causal in promoting dissociation of Beclin1 from BCL-2, and in promoting autophagy." | 1.35 | Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. ( Dent, P; Graf, M; Grant, S; Houghton, PJ; Mitchell, C; Park, MA; Rahmani, M; Voelkel-Johnson, C; Walker, T; Yacoub, A, 2009) |
| "Lastly, the first effective medical treatment of hepatocellular carcinoma has been presented." | 1.35 | [News in digestive oncology]. ( Di Fiore, F; Michel, P, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.69) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Arçay, A | 1 |
| Eiber, M | 1 |
| Langbein, T | 1 |
| Tseng, JC | 1 |
| Narayanan, N | 1 |
| Ho, G | 1 |
| Groves, K | 1 |
| Delaney, J | 1 |
| Bao, B | 1 |
| Zhang, J | 2 |
| Morin, J | 1 |
| Kossodo, S | 1 |
| Rajopadhye, M | 1 |
| Peterson, JD | 1 |
| Zheng, X | 1 |
| He, K | 1 |
| Zhang, L | 1 |
| Yu, J | 1 |
| Toledo, M | 1 |
| Penna, F | 1 |
| Busquets, S | 1 |
| López-Soriano, FJ | 1 |
| Argilés, JM | 1 |
| Fiskus, W | 1 |
| Mitsiades, N | 1 |
| Fritsche-Guenther, R | 1 |
| Witzel, F | 1 |
| Kempa, S | 1 |
| Brummer, T | 1 |
| Sers, C | 2 |
| Blüthgen, N | 1 |
| Du, J | 1 |
| Wang, Y | 1 |
| Chen, D | 1 |
| Ji, G | 1 |
| Ma, Q | 1 |
| Liao, S | 1 |
| Zheng, Y | 1 |
| Hou, Y | 1 |
| Li, Y | 1 |
| Tan, T | 1 |
| Zheng, J | 1 |
| Zhang, C | 1 |
| Beauparlant, P | 1 |
| Bédard, D | 1 |
| Bernier, C | 1 |
| Chan, H | 1 |
| Gilbert, K | 1 |
| Goulet, D | 1 |
| Gratton, MO | 1 |
| Lavoie, M | 1 |
| Roulston, A | 1 |
| Turcotte, E | 1 |
| Watson, M | 1 |
| Walker, T | 1 |
| Mitchell, C | 1 |
| Park, MA | 1 |
| Yacoub, A | 1 |
| Graf, M | 1 |
| Rahmani, M | 1 |
| Houghton, PJ | 1 |
| Voelkel-Johnson, C | 1 |
| Grant, S | 1 |
| Dent, P | 1 |
| Kuner, R | 1 |
| Falk, CS | 1 |
| Lund, P | 1 |
| Sueltmann, H | 1 |
| Braun, M | 1 |
| Buness, A | 1 |
| Ruschhaupt, M | 1 |
| Conrad, J | 1 |
| Mang-Fatehi, S | 1 |
| Stelniec, I | 1 |
| Krapfenbauer, U | 1 |
| Poustka, A | 1 |
| Schäfer, R | 1 |
| Puca, R | 1 |
| Nardinocchi, L | 1 |
| Starace, G | 1 |
| Rechavi, G | 1 |
| Sacchi, A | 1 |
| Givol, D | 1 |
| D'Orazi, G | 1 |
| Awada, A | 2 |
| Gil, T | 1 |
| Whenham, N | 1 |
| Van Hamme, J | 1 |
| Besse-Hammer, T | 1 |
| Brendel, E | 2 |
| Delesen, H | 1 |
| Joosten, MC | 1 |
| Lathia, CD | 1 |
| Loembé, BA | 1 |
| Piccart-Ghebart, M | 1 |
| Hendlisz, A | 1 |
| Weisshaupt, Ch | 1 |
| Budak, K | 1 |
| Pestalozzi, B | 1 |
| Sato, T | 1 |
| Stange, DE | 1 |
| Ferrante, M | 1 |
| Vries, RG | 1 |
| Van Es, JH | 1 |
| Van den Brink, S | 1 |
| Van Houdt, WJ | 1 |
| Pronk, A | 1 |
| Van Gorp, J | 1 |
| Siersema, PD | 1 |
| Clevers, H | 1 |
| Lau, KS | 1 |
| Zhang, T | 1 |
| Kendall, KR | 1 |
| Lauffenburger, D | 1 |
| Gray, NS | 1 |
| Haigis, KM | 1 |
| Pennarun, B | 1 |
| Kleibeuker, JH | 1 |
| Boersma-van Ek, W | 1 |
| Kruyt, FA | 1 |
| Hollema, H | 1 |
| de Vries, EG | 1 |
| de Jong, S | 1 |
| Heim, M | 1 |
| Sharifi, M | 1 |
| Hilger, RA | 2 |
| Scheulen, ME | 2 |
| Seeber, S | 2 |
| Strumberg, D | 2 |
| van Laarhoven, HW | 2 |
| Bussink, J | 2 |
| Lok, J | 2 |
| Punt, CJ | 2 |
| Heerschap, A | 2 |
| van Der Kogel, AJ | 2 |
| Richly, H | 1 |
| Schleucher, N | 1 |
| Korfee, S | 1 |
| Tewes, M | 1 |
| Faghih, M | 1 |
| Voliotis, D | 1 |
| Haase, CG | 1 |
| Schwartz, B | 1 |
| Voigtmann, R | 1 |
| Verhagen, I | 1 |
| Kaanders, JH | 1 |
| Michel, P | 1 |
| Di Fiore, F | 1 |
| Hirst, DG | 1 |
| Joiner, B | 1 |
| Hirst, VK | 1 |
| Honess, DJ | 1 |
| Hill, SA | 1 |
| Collingridge, DR | 1 |
| Edwards, B | 1 |
| Brauers, G | 1 |
| Powell, NA | 1 |
| Chaplin, DJ | 1 |
| Buch, L | 1 |
| Streeter, D | 1 |
| Halpern, RM | 1 |
| Simon, LN | 1 |
| Stout, MG | 1 |
| Smith, RA | 1 |
| Pitt, WW | 1 |
| Scott, CD | 1 |
| Jones, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors[NCT06077591] | 40 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| Drug Response in Patient-derived Organoids Models of Advanced or Recurrent Ovarian Cancer, an Exploratory Research[NCT05290961] | 30 participants (Anticipated) | Observational [Patient Registry] | 2022-03-09 | Recruiting | |||
| Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study[NCT02636426] | Phase 1 | 17 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors[NCT00933777] | Phase 1 | 36 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for niacinamide and Cancer of Colon
| Article | Year |
|---|---|
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2011 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort | 2005 |
24 other studies available for niacinamide and Cancer of Colon
| Article | Year |
|---|---|
Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET.
Topics: Adenocarcinoma; Aged; Biological Transport; Colonic Neoplasms; Humans; Incidental Findings; Male; Ni | 2020 |
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Respo | 2017 |
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic | 2013 |
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Topics: Animals; Antineoplastic Agents; Cachexia; Carcinoma, Lewis Lung; Colon; Colonic Neoplasms; Lung; Mel | 2014 |
B-Raf Inhibition in the Clinic: Present and Future.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MA | 2016 |
Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Topics: Apoptosis; Benzimidazoles; Blotting, Western; Cell Proliferation; Colonic Neoplasms; Gene Expression | 2016 |
BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2016 |
[A comparison on radiochemical behavior and biological property of antisense oligonucleotide labeled with technetium-99m by two methods: NHS-MAG3 versus SHNHP].
Topics: Animals; Colonic Neoplasms; Glycine; Humans; Isotope Labeling; Mice; Mice, Inbred BALB C; Niacinamid | 2008 |
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line, Tumor; Colonic Neo | 2009 |
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzenesulf | 2009 |
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Butadienes; Colonic Neoplasms; DNA (Cytosine-5-)-Methyltra | 2009 |
Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis.
Topics: Acetylation; Apoptosis; Breast Neoplasms; Carcinoma; Carrier Proteins; Cell Line, Tumor; Cloning, Mo | 2010 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Aged, 80 and over; Animals; Barrett Esophagus; Biopsy; Cell Cu | 2011 |
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Aged, 80 and over; Animals; Barrett Esophagus; Biopsy; Cell Cu | 2011 |
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Aged, 80 and over; Animals; Barrett Esophagus; Biopsy; Cell Cu | 2011 |
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Aged, 80 and over; Animals; Barrett Esophagus; Biopsy; Cell Cu | 2011 |
BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner.
Topics: Antineoplastic Agents; Catalytic Domain; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Sepa | 2012 |
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Asp | 2013 |
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; | 2003 |
Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters.
Topics: Animals; Benzimidazoles; Bromodeoxyuridine; Carbon Dioxide; Cell Hypoxia; Cell Line, Tumor; Colonic | 2004 |
Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen.
Topics: Animals; Carbon Dioxide; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Colonic Neop | 2005 |
[News in digestive oncology].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Comb | 2008 |
Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites.
Topics: Animals; Cardiac Output; Colonic Neoplasms; Male; Mammary Neoplasms, Experimental; Metoclopramide; M | 1993 |
Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo.
Topics: Adenocarcinoma; Animals; Carbon Dioxide; Carcinoma; Cell Hypoxia; Colonic Neoplasms; Contrast Media; | 1998 |
Inhibition of transfer ribonucleic acid methylase activity from several human tumors by nicotinamide and nicotinamide analogs.
Topics: Adenocarcinoma; Aldehydes; Amines; Animals; Carbon Isotopes; Carcinoma; Carcinoma 256, Walker; Cell | 1972 |
Simultaneous multicolumn operation of the UV-analyzer for body fluids.
Topics: Autoanalysis; Body Fluids; Chemistry, Clinical; Chromatography, Ion Exchange; Colonic Neoplasms; Hum | 1972 |